Indee Labs Issued United States and International Patents for Intracellular Delivery System

Indee Labs announces issuance of patents in the United States, Canada, Japan and Australia for intracellular delivery with a system for microfluidic vortex shedding

BERKELEY, Calif.--(BUSINESS WIRE)--Indee Labs, a biotechnology company developing a scalable, non-viral intracellular delivery system based on microfluidic vortex shedding (µVS), today announced the United States Patent Office has issued U.S. Patent No. 10,501,716 covering a system for introducing exogenous material to cells with microfluidic vortex shedding. Similar patents have already been granted in Canada, Japan and Australia with additional jurisdictions pending. The Indee Labs group of companies is assigned and has exclusive rights to all patents, patent applications and proprietary information.

“We are excited to announce exclusive rights to our core technology, intracellular delivery with microfluidic vortex shedding, in multiple major jurisdictions including the United States,” stated Ryan Pawell, CEO of Indee Labs. “This patent is an important part of our growing portfolio and covers the system required for the intracellular delivery of exogenous materials to cells with µVS.”

The team at Indee Labs have made multiple advancements in the field of intracellular delivery. Key advantages of µVS include high yield of modified cells with rapid processing of µL- and mL-scale samples also resulting in negligible perturbation of the immune cell state. More detail is available in Nature Scientific Reports.

About Indee Labs

Indee Labs is a biotechnology company developing scalable hardware for intracellular delivery using microfluidic vortex shedding (µVS). The Indee Labs team has already demonstrated revolutionary improvements over existing methods including scalability, high yield (i.e. recovery, viability and efficiency), negligible perturbation of the immune cell state along with rapid processing of research-, clinical- and commercial-scale samples with a simple workflow and a small footprint.

These promising early results have led to various forms of seed-stage support in both Australia (i.e. AusIndustry, Main Sequence Ventures, MTP Connect and NSW Health Medical Device Fund) and the United States (i.e. IndieBio/SOSV, Y Combinator, Social Capital, Founders Funds’ FF Science, and Axial). More information is available at


Ryan Pawell
Chief Executive Officer
+1 949 500 6965